Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, ADAPTIMMUNE THERAPEUTICS PLC reported revenue of $178M, up 195.3% year over year. Operating margin was -38.6% and net margin -39.8%, on a free-cash-flow margin of -41.6% with capital expenditure at 0.5% of revenue. Every figure is computed directly from ADAPY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $178M | -38.6% | -39.8% |
| FY2023 | $60M | -231.8% | -188.9% |
| FY2022 | $27M | -604.0% | -609.5% |
| FY2021 | $6M | -2638.6% | -2571.0% |
| FY2020 | $4M | -3370.5% | -3286.8% |
How does ADAPY compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.